Skip to the page

Data / Form D filings / Lirum Therapeutics, Inc.

Lirum Therapeutics, Inc.: Form D filing

Lirum Therapeutics, Inc., a biotechnology company in New York, NY, filed a Form D with the SEC in 2023. The latest, on February 23, 2023, reports $6.3 million sold of a $10 million offering to 53 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
590 MADISON AVENUE, 21ST FLOOR, New York, NY, 10022
Phone
(917) 376-2350
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2021
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1965411

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Feb 23, 2023New notice$10,000,000$6,300,000$3,700,00053Feb 8, 2023sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Daniel HumeDirector
Kenneth HobermanExecutive Officer, Director
Mark SardDirector
Ivan BergsteinDirector

Other biotechnology companies in New York that filed recently

Every Form D from the week of Feb 20, 2023 · All recent filings in New York · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Lirum Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.